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An important strategic decision was made by the Na-
tional Agency for Medicines (NAM) in April with the
aim of increasing its impact on EU issues. 1
In co-operation with the EU, the NAM will in the
coming years concentrate on issues in the sectors of bio-
logical products and medicinal products for paediatric
use. In the biological products sector the emphasis lies
especially on gene and cell therapy medicinal products
and biotechnological products. The future strategy of
the NAM in this changing and expanding area of medi-
cines control within the EU can thereby be reinforced.
Efforts to centralise the regulatory work regarding
new innovations will continue in the expanded union of
25 member states. Rational, high quality and resource-
saving co-operation requires sensible sharing of duties
and expertise among the authorities. It is also not credi-
ble that every agency, not even a large national institu-
tion, could be an expert in every area.
The NAM has great opportunities of success in the
chosen areas of focus. The Agency has already devel-
oped expertise and know-how in the fields of biological
products and medicinal products for paediatric use, and
further development is to be expected. It is important
that the front-rank Finnish expertise in these areas will
be linked with the network of co-operation and experts
of the Agency. The NAM wants to place itself in the
forefront of the development of regulatory practices for
advanced therapy medicinal products and their evalua-
tion. The coming EU legislation covering medicinal
products for paediatric use opens up new opportunities
of influence.
With its areas of focus chosen the NAM nevertheless
does not intend to neglect its future responsibilities in
other areas of EU co-operation. The primary duties will
be attended to without being hindered in any way.
Notwithstanding this, the emphasis from now on will lie
on, and important influential efforts will be concentrat-
ed on, the biological products and medicinal products
for paediatric use.
The NAM is probably the first national medicines
agency to reveal the strategy, which it has chosen for
implementation in future co-operation within the regu-
latory work. It may well be that other drug authorities
are making the same choices. In that case, we will have
a case of co-operation and shared work opportunities,
for which the chosen areas of focus, being as extensive
as they are, will provide considerable opportunity. It
would also be desirable for national centres of excel-
lence to develop within the various areas of medicines
control. In this way, sensibly shared duties would secure
and promote public health of EU citizens in an ever
more effective way.
We, at the National Agency for Medicines, would
like to see that the choices made will be helpful to the
research efforts in the pharmaceutical industry when the
suitability of our Agency is considered for the responsi-
bilities of evaluation, scientific advice and other expert
assignments at the EU level. Biological products and the
medical treatment of children are both extensive sectors
under development and no doubt would be included in
the research programmes of many pharmaceutical com-
panies.
1 See www.nam.fi, 6.4.2004 
Hannes Wahlroos
PROFESSOR, DIRECTOR GENERAL
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Biological products and medicinal products for
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The targets of attention have been
chosen by the National Agency for
Medicines (NAM) and will be used
to build up the strategy for the fu-
ture and the conditions for credible
and successful operation in the
changing and developing field of ac-
tivity. The enlargement of the EU
will lead to the regulatory authori-
ties of another 10 member states be-
ing able to share in the extensive
area of responsibilities. It goes with-
out saying that in order to achieve
the best possible results the founda-
tions of effective work by the Euro-
pean authorities must be laid not
only on co-operation but also on
specialisation.
Following discussions in the
Agency, the areas of focus that have
been chosen are biological medicines
and paediatric drug therapy. Primar-
ily, the choices will mean not only
that the NAM will make a special
contribution to EU co-operation es-
pecially in these areas of work, but
will also naturally ensure that all of
the authorities’ duties will be carried
out in an appropriate manner. The
work will be systematically built up
on the foundations of existing skills
and competences. 
Biological medicines 
Biological products constitute a het-
erogeneous group. The conventional
biological products include blood
products, which have a key role in
the healthcare system and which are
partly covered by medicinal product
regulation and partly by regulation
of blood transfusion service opera-
tions. Vaccines are probably the
most important medicines from the
public health viewpoint. Most recent
biotechnological medicines have
been produced by using recombi-
nant DNA or hybridoma technolo-
gy. They have, for example, attained
an important position in the treat-
ment of diabetes and rheumatic and
autoimmune diseases. Gene therapy
and cell therapy are recent members
in the group of biologicals; their
most ambitious target is the recov-
ery of tissue and organ functions
lost due to congenital or aquired
diseases. 
Despite domestic setbacks in re-
cent years, biological medicines are
the fastest-growing group of medi-
cine. About a third of the medicinal
products being developed nowadays
belong to this category. The authori-
ties are faced with major challenges
in the regulation of biological prod-
ucts. The development and regula-
tion of new medicines is based not
only on pharmacy and pharmacolo-
gy, but also on cell and molecular
biology, as well as immunology.
Regulation makes use of the most
recent scientific data, since the
guidelines are not yet adequately de-
veloped or have to be finetuned on
case by case basis. The choice and
testing of raw materials and fool-
proof regulation of production
methods are important means to en-
sure the safety of use of biological
medicines, especially the safety of
protecting against contamination
with infective agents.
The regulation of biological
products has always enjoyed a spe-
cial status. Special legal require-
ments have been stipulated for
blood products and vaccines, such
as official product batch release. The
centralised process for marketing
authorisations for biotechnological
medicines was adopted by the EU as
early as 1987. 
In recent years, by recruitment of
experts and networking, the NAM
has improved its expertise in the
regulation of biological medicines.
Experts of the NAM have partici-
pated in the scientific advise work,
in the evaluation of marketing au-
thorisations as rapporteurs  and in
the community referral processes
dealing with biologicals. Experts
from the Finnish Agency have often
played a central role in the prepara-
tion of EU guidelines for biotechno-
logical products.
The development of the biologi-
cal products sector into a pivotal
area started years ago. Nevertheless,
the choice of biological products as
one of the areas of focus in the
process of exerting influence on the
EU poses a considerable challenge.
The quality and consistency of both
scientific and administrative work in
the special areas of focus need to be
consilidated through continuous im-
provement of  the skills required as
well as trough increased interaction
with academia. The small size of the
Agency may be advantageous when
trying to establish smooth collabora-
tion of experts in biotechnology,
pharmacy, toxicology and pharma-
cology in certain predetermined sec-
tors of biotechnology.
Paediatric drug therapy 
From the viewpoint of public health,
paediatric drug therapy make up a
very important but inadequately re-
garded field of pharmaceutical de-
velopment. About 20% of the popu-
lation within the EU area is under
16 years of age. These children and
adolescents suffer from the same dis-
eases as adults do, but in addition,
they suffer from diseases absent in
the adult population. The number of
medicinal products authorised for
marketing and intended for use in
Olavi Tokola Pekka Kurki Markku Toivonen
PROFESSOR, HEAD OF DEPARTMENT HEAD OF SECTION HEAD OF SECTION
Department of Marketing Authorisati0ns
The National Agency for Medicines is focusing
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children is restricted, since the phar-
maceutical industry is producing
new medicinal products primarily
for use in adults. To a large extent,
children are prescribed medicinal
products on the basis of data col-
lected from the experience gained in
adults without appropriate trials
and using pharmaceutical forms
which are not designed for the needs
of children. Should trials exist, they
have not necessarily been submitted
to the authorities for evaluation. Le-
gal grounds for the EU authorities
to demand such trials do not exist at
present. Medicines for paediatric pa-
tients are typically developed in
stages, and it may not necessarily be
possible to launch trials concomi-
tantly in different age groups, which
may lead to a long delay.
The situation can be rectified on-
ly by legislative measures. The Com-
mission issued a draft regulation on
8.3.2004 regarding medicinal prod-
ucts intended for paediatric use. Pro-
motion of the status and health of
children is the primary aim of the
draft regulation. This is done by 1)
promoting the development of new
medicinal products and pharmaceu-
tical forms for children, 2) ensuring
that the medicinal products indicat-
ed for the treatment of children are
based on a high level of research
and authorisation processes, and 3)
increasing and improving the infor-
mation available about the effects of
medicinal products on children. Sup-
port and incentives will be available
for the pharmaceutical industry in
its development work.
The key principle of the draft
regulation is that every new appli-
cant for a marketing authorisation
for a new medicinal product must
submit a paediatric development
plan to the Board of Medicinal
Products for Paediatric Use, which is
to be established within the Euro-
pean Medicines Agency (EMEA),
before the application for marketing
authorisation is even considered for
evaluation. The applicant may re-
quest a waiver from having to sub-
mit a paediatric development plan
or request a postponement for the
submission. A waiver can be granted
under certain conditions. The aim is
that the introduction of new impor-
tant medicinal products indicated
for adult use should not in any way
be delayed. The draft regulation also
stipulates that all paediatric trials as-
sociated with medicinal products
which have a marketing authorisa-
tion in the EC must be submitted to
the EMEA or to the national au-
thority for evaluation within a year
from the enforcement of the regula-
tion. Once properly followed, these
obligations are a significant chal-
lenge to the industry and the author-
ities. The aim of the draft regulation
is also to ensure that the quality, ef-
ficacy and safety of old medicinal
products, which have already lost
the protection of their patent, are al-
so investigated in cases where they
are currently being used in children.
The NAM keeps a keen eye on
the preparatory work associated
with the regulation and is preparing
itself to accept the associated chal-
lenges in pre- and post-authorisation
control of medicinal products for
paediatric use, both at the national
and the EU level. This involves ac-
tive participation in the work of the
Board of Medicinal Products for
Paediatric Use, which is to be estab-
lished, by offering, for example, nec-
essary expertise and accepting duties
of evaluation respecting paediatric
development plans and completed
trials. Updating the data on medici-
nal products with national market-
ing authorisation is also an impor-
tant aim. The Agency is already ac-
tively participating in the work of
the paediatric expert group of the
EMEA, the responsibilities of which
include mapping out the problem ar-
eas in the medical treatment of chil-
dren.
Scientific advice is available upon
request regarding the conduct of
tests and trials necessary to prove
the quality, efficacy and safety of
medicinal products indicated for use
in children. The NAM has, for ex-
ample, provided national advice and
information relative to the develop-
ment of pharmaceutical forms ap-
propriate for use in children, and it
takes an active part in the scientific
advisory role of the EMEA by offer-
ing Finnish expertise and accepting
responsibilities for co-ordinating the
advice.
In-house training and support for
the setting-up and maintenance of a
network of experts are envisaged for
enhancement of the expertise. The
choice of biological medicinal prod-
ucts and medicinal products for pae-
diatric use as the area of focus offers
some advantages of synergy, because
an ever-increasing number of the
more recent medicinal products are
classified as biological medicinal
products. Many of the diseases
treated with medicinal products
based on gene and cell therapy ap-
pear already in childhood.
Conclusion
Biological medicinal products and
medicinal products for paediatric
use are important from the view-
point of public health. To be able to
exert influence in this area, the
Agency needs good networks of co-
operation and the continuous devel-
opment of expertise and quality sys-
tems.
In May 2004, the EMEA carried
out a survey among the national au-
thorities on their strengths, poten-
tials and targets of interest in the
field of European medicinal product
regulation. The decisions made by
the Finnish Agency were timely and
made it easier for Finland to com-
plete the survey. The chosen areas of
focus will gradually increase their
share of the Agency’s work involv-
ing its role as a rapporteur, its duties
as a reference member state, its sci-
entific advisory role, its choices of
chairmen and the preparatory ef-
forts of working groups, and its
aims with respect to developing the
skills of its staff, as well as in work
involving post-authorisation control,
pharmaco-vigilance and inspections.
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The male testosterone production is
significantly reduced after middle
age. Unlike menopause in women,
the male climactericium, i.e. andro-
pause is a continuous, slowly ad-
vancing process.
Decreased fertility is due mainly
to slowly diminished sexual activity
and not so much to changes in sper-
matogenesis. Sperm quality and
motility are of course impaired, but
the volume density of spermatozoa
remains fairly constant. This is at
least partly caused by the reduced
frequency and volume of ejacula-
tions. The concentration of free
testosterone in the circulating blood
is reduced by an average of one per-
cent annually after the age of 40,
leading to 30–40% lower concentra-
tions in 70-year-olds compared with
young men. The diurnal differences
of testosterone secretion also even
out with age. The reduction in free
testosterone is associated with an in-
creased amount of sex-hormone-
binding globulin in the circulating
blood. The exact cause of this is un-
known, and neither is the reduction
explained by the increased oestrogen
to androgen ratio alone. Testos-
terone is changed to oestrogen and
dihydrotestosterone (DHT), which 
is the most important active andro-
gen in most tissues, including the
prostate. The DHT concentration in
the circulating blood remains fairly
unchanged in elderly men. The pro-
duction of androgen in the male
adrenal gland is also beginning to
fall after the age of 30, and in the
over 70-year-olds it has dropped
down to a third.
Why do androgens decrease?
The reduced number of Leydig cells,
which produce androgens, and re-
duced blood circulation, causes the
reduction in the testicular androgen
production. The effect of the hypo-
thalamus-secreted GnRH on the an-
terior pituitary and the tissue sensi-
tivity to androgens are also reduced.
Androgen deficiency classified as hy-
pogonadism is found in less than
10% of men under the age of 60,
but in at least 20% of the over 60-
year-olds. There are significant indi-
vidual variations and the testos-
terone concentration in some
healthy men over the age of 80 is
still equal to that of young adults.
The reduced secretion and effect of
androgen should distinctly increase
the pituitary LH secretion. This is
not always the case, however, and
the LH levels in elderly men are of-
ten only slightly elevated or normal.
This is an indication of reduced sen-
sitivity of the hypothalamus-pitu-
itary-testicle axis to hormonal feed-
back effects.
Andropause
The reduced hormonal function of
the testicles and its associated
changes are known as partial andro-
gen deficiency of the ageing male
(PADAM) or androgen decline in
the ageing male (ADAM). Typical
symptoms of andropause include re-
duced vitality, tiredness, irritability,
depression, reduced sexual desire,
sweating and hot flushes and also
reduced muscle mass and strength.
Memory impairment is also consid-
ered to be associated with reduced
androgen levels. Many diseases, un-
healthy life style such as smoking,
high consumption of alcohol and
lack of exercise encourage the reduc-
tion in androgen levels. Erection dis-
turbances are common in ageing
men. Less than a quarter of 40–45-
year-old Finnish men suffer to some
degree from erection disturbances,
but they occur in nearly all 65–70-
year-olds at least occasionally. Nev-
ertheless, only about 15% of the
cases can be explained by androgen
deficiency.
Diagnostics and treatment of 
andropause
Androgen deficiency due to ageing is
not always easy to detect, because
most often it is a question of a rela-
tive deficiency, which causes symp-
toms of various degrees. Among
clinical symptoms, night-time and
morning erections correspond per-
haps best to androgen concentra-
tions. Erections occurring at a rate
of less than one per week may be a
sign of androgen deficiency. Lack of
sexual desire may also indicate
testosterone deficiency. Besides care-
ful tracing of symptoms and clinical
investigations, the initiation of an-
drogen therapy should always be
based on an assessment of the
testosterone level. However, a serum
testosterone level, which is low or
even within the normal limits, does
not necessarily reveal the whole
truth. The weight and weight index
of the male are ignored in testos-
terone reference values. If the total
testosterone in an overweight male
with apple type obesity is low, the
free testosterone level may still be
within normal limits because of high
insulin concentrations and a low
binding protein level. Similarly, a
thin male may exhibit significant
symptoms even at relatively high
testosterone levels. If distinct symp-
toms of andropause are exhibited
and the serum testosterone is below
10 nmol/l, androgen therapy is often
beneficial to the male. At levels of
10–15 nmol/l, treatment for a trial
period of 3–6 months may be con-
sidered and any alleviation of symp-
toms monitored.
Male menopause
Juha Tapanainen
PROFESSOR
Department of Obstetrics and Gynaecology
Oulu University Hospital
Summary 
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Testosterone products
Testosterone treatment may be ad-
ministered orally, by intramuscular
injection, or cutaneously in plasters
and gel products. Testosterone levels
achieved by an oral testosterone de-
rivative vary considerably, depend-
ing on the absorption and liver
breakdown of the medicinal sub-
stance. Because of the rapid break-
down, the product should be taken
three times a day to obtain a bal-
anced hormonal effect. The most
common product is testosterone un-
decenoate, which is administered at
a dose of 80 mg in the morning and
40 mg during the day and in the
evening. Some men may require a
daily dose of as high as 240 mg. By
using this method of administration,
excessive increases in the testos-
terone level are avoided. 
A testosterone injection
(200–250 mg) is administered at in-
tervals of 3–4 weeks. Steady concen-
trations are achieved by daily testos-
terone plasters, or gels, or depot in-
jection which will be administrated
im. in 3-4 months’ intervall. 
The efficacy of hormone treat-
ment is assessed at a doctor’s ap-
pointment after 3–6 months. Mea-
surements of serum testosterone lev-
els are usually of no benefit because
of the reduced secretion of endoge-
nous testosterone and other andro-
gens, and a radioimmunological as-
say is not helpful in the assessment
of bioactive androgen levels. Subjec-
tive clinical responses are therefore
the most important parameter of re-
sponse.
Adverse reactions 
Androgens used in replacement ther-
apy have relatively few adverse ef-
fects. Greasy skin, acne, breast ten-
derness/enlargement and oedema in
the limbs may be signs of an exces-
sive dose. The lipid effects of andro-
gen are dependent on the product
and the dose, but physiological
treatment has an insignificant effect
on the fat values. Liver function dis-
orders are rare during treatment.
They may occur in the use of methy-
lated testosterone products, but
products devoid of methyl testos-
terone content are usually safe to
use. It is recommended that choles-
terol and liver enzyme levels be
checked at the start of treatment.
Androgens accelerate erythropoiesis,
and consequently, the haemoglobin
and haematocrit levels should be as-
sessed annually and the dose re-
duced as necessary. This is usually
not a problem if the initial levels of
testosterone are distinctly low. On
the other hand, in the treatment of a
relative androgen deficiency, the
haemoglobin and haematocrit levels
may increase significantly. Long-
term androgen therapy may delay
spermatogenesis due to reduced se-
cretion of gonadotrophin, but ac-
cording to available data the
changes are reversible.
Prostate cancer must be excluded
prior to the start of the treatment.
Palpation of the prostate via the
anus and evaluation of the serum
prostate specific antigen (PSA) are
usually sufficient. Androgen therapy
has not been found to increase the
occurrence of prostate cancer, but it
may promote the advancement of
existing cancer. As the follow-up
times of androgen treatment are still
relatively short, the prostate and
PSA should be examined every year.
For the same reason, the treatment
should be withdrawn if it is of no
definite benefit to the patient. No
definitive adverse effects on benign
prostatic hyperplasia have been de-
tected with androgen replacement
therapy. The occurrence of sleep ap-
noea may increase during testos-
terone therapy. The blood oestradiol
concentration is increased by testos-
terone therapy, which results in a
relatively frequent occurrence of gy-
naecomastia in elderly males.
Conclusion
Ageing is accompanied by a number
of symptoms and complaints, some
of which are associated with an-
dropause. The most important
symptoms distinctly associated with
the reduction in androgen levels in-
clude changes relating to general
wellbeing and libido. Since nearly all
changes, both physiological and
pathological, linked with ageing, are
caused by several factors, it is often
difficult to decide whether the symp-
toms exhibited are a result of re-
duced testosterone levels and
whether androgen replacement ther-
apy would be of use. Initiation of
the treatment should be based on
both past medical history and evalu-
ation of the testosterone level. The
efficacy and necessity of androgen
therapy can be established with a
couple of months’ trial therapy. If a
distinct response is not achieved
within half a year, treatment with
the same product is not recommend-
ed, because the risks of long-term
therapy are not very well known. It
should be borne in mind that only
some males require testosterone
therapy and find it beneficial. A
large proportion of males becomes
grey and old happily without recog-
nising any androgen deficiency. Let’s
not get involved in unnecessary ex-
aminations and therapies without
distinct symptoms and findings in-
dicative of a hormone deficiency.
A n d r o g e n p r o d u c t s D o s a g e
Oral products testosterone undecanoate capsules  40 mg 120–160 mg/day
mesterolone tablets  25 mg 25–75 mg/day
Dermal preparations testosterone plaster 2,5 mg/24 h and 5 mg/24 h 2,5–5 mg/day
testosterone gel 50 mg/dose dosepack/day
Injection testosterone propionate/phenylpropionate/ 250 mg in 3–4 weeks’ intervall 
-isocaproat/decanoat 
Depot injection testosterone undecanoat 1000 mg/dose 1000 mg in 3–4 months’ intervall 
38 TABU 3.2004
In relation to drug consumption, the
proportion of skin reactions caused
by medicinal substances is estimated
at 2%. Indications of the prevalence
of skin reactions in relation to other
adverse drug reactions are probably
to be seen in the fact that 5,862, or
30% of all reports received by the
Agency in 1973–2003, were associ-
ated with suspected reactions in the
skin or subcutaneous tissue.
In the various drug groups ad-
verse skin reactions were most com-
monly reported with the use of anti-
infectives for systemic use, drugs for
cardiovascular diseases, and drugs
having an effect on the nervous sys-
tem (Fig.). The five most commonly
reported categories of ADRs covered
almost 75% of all adverse reactions
of the skin and subcutaneous tissue,
three of them being urticaria (24%
of all reports), more general “rash”
(22%) and erythematous rash
(17%).
Angioedema
A total of 124 cases of angioedema
(2% of all reports), manifested as
oedema of the subcutaneous tissue
and mucous membranes, was re-
ported during 1973–2003. The high-
est number of reports were of drugs
used in cardiovascular diseases, and
in almost half of the cases of angio-
edema, i.e. 49 reports, the suspected
medicinal substancies were ACE in-
hibitors, while 11 reports were con-
cerned with a combination of an
ACE inhibitor and a thiazide diuret-
ic. A total of 34 reports on ACE in-
hibitors were associated with enal-
april. The next most commonly re-
ported cases of angioedema were as-
sociated with the use of losartan and
a combination of losartan and a thi-
azide diuretic (7 reports) and the use
of acetylsalicylic acid (4 reports).
Erythema fixum
Erythema fixum is almost without
exception regarded as a skin reac-
tion caused only by medicinal sub-
stances. On recurrence it always
reappears in the same skin areas.
The ADR database of the NAM
contains 100 reports of erythema
Adverse drug reactions involving the skin and
subcutaneous tissue reported to the National
Agency for Medicines during 1973–2003
Jyrki Vanakoski
SENIOR MEDICAL OFFICER
Leena Sommarberg
RESEARCHER
Safety&Drug Information
National Agency for Medicines
Summary 
ADR News
Various skin reactions are thought to be the most common ADRs, but for a number of reasons it
is difficult to obtain a definite picture of exactly how common they are. Drug reactions, by the
symptoms they exhibit, do not normally differ from skin reactions arising from other causes. Fur-
thermore, undefined skin reactions, and particularly reactions with mild symptoms may easily go
unreported.
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fixum over the past 30 years. The
most commonly reported reactions
were manifested during the use of
doxycycline (15 reports) and
sulphonamide and trimethoprim and
their fixed combinations (12 re-
ports). In the 1970s and 1980s,
fixed analgesic combinations con-
taining phenazone, which have since
been withdrawn from the market,
were the most common group of
products (12 reports) associated
with erythema fixum reactions.
Photosensitivity reactions
Medicinal substances known for the
photosensitivity reactions they cause
include doxycycline, fluoroquinol-
ones, chlorpromazine among neu-
roleptics, and some topically applied
anti-inflammatory analgesics. The
95 cases of photosensitivity reported
are fairly evenly distributed over the
various active agents or their combi-
nations. The most commonly report-
ed products were a combination of
amiloride and hydrochlorthiazide (9
reports), and doxycycline (7 re-
ports). Six reports of adverse drug
reactions were associated with the
use of sulphonamides and combina-
tions of them with trimethoprim,
and with the use of anti-inflammato-
ry analgesics such as piroxicam and
ketoprofen; the reports of the latter
were, all but one, associated with a
pharmaceutical form intended for
topical use.
Serious skin reactions
Erythema multiforme and the more
serious Stevens-Johnson syndrome
and toxic epidermal necrolysis
(Lyell’s syndrome) are nowadays
classified as different forms of the
same syndrome. In addition to blis-
ters on the skin, Stevens-Johnson
syndrome is associated with blisters
on the mucous membranes and gen-
eral symptoms, e.g. fever. Due to the
necrosis of extensive areas of skin
associated with toxic epidermal
necrolysis, and due to the damage to
the mucous membranes, intensive
care is indicated, and the state is of-
ten life-threatening. The number of
reactions suspected to have been as-
sociated with drug exposure during
1973–2003 was 291, i.e. 5% of all
skin reactions. A total of 152 re-
ports were associated with erythema
multiforme, 105 with Stevens-John-
son syndrome  and 34 with toxic
epidermal necrolysis. Over half of
the reported cases of Stevens-John-
son syndrome and all of those of
toxic epidermal necrolysis were clas-
sified as serious adverse reactions. In
addition, six of the cases of toxic
epidermal necrolysis caused a pa-
tient’s death. Of all the reports, 73
reactions were suspected of having
been caused by sulphonamides,
trimethoprim or their combination.
Other most commonly reported in-
dividual medicinal substances in-
cluded terbinafine (19 reports), car-
bamazepine (17 reports) and sul-
phasalazine and phenytoin (9 re-
ports of each). In the reports associ-
ated with toxic epidermal necrolysis,
the most commonly suspected medi-
cinal substances after sulphonamides
and trimethoprim were carbamaz-
epine and phenytoin.
Conclusion
Reactions of the skin and subcuta-
neous tissues are some of the most
commonly reported ADRs. The ma-
jority of them are nevertheless mild,
and withdrawal of the medicinal
substance and its subsequent avoid-
ance as far as possible are usually
adequate as treatment. At the same
time, however, it needs to be borne
in mind that a small proportion of
the skin and mucous membrane re-
actions may be life-threatening, and
that they may be induced by the
same commonly used medicinal sub-
stances as those which have been in
use when a mild reaction has oc-
curred.
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